

[SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:190, SEQ ID NO:191,] SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, or SEQ ID NO:206;

(b) a pre-pro region of a persephin polynucleotide as set forth in [SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:192, SEQ ID NO:193,] SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, or SEQ ID NO:216;

(c) a pre- region of a persephin polynucleotide as set forth in SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, or SEQ ID NO:210;

(d) a pro- region of a persephin polynucleotide as set forth in SEQ ID NO:211, or SEQ ID NO:212; or

(e) a fragment thereof comprising at least 15 contiguous nucleotides.

30. The isolated and purified nucleic acid molecule or nucleic acid molecule complementary thereto of claim 28, which specifically hybridizes to [SEQ ID NO:183, SEQ ID NO:194,] SEQ ID NO:199, or SEQ ID NO:201.

37. The nucleic acid molecule or nucleic acid molecule complementary thereto or fragment of claim 34, which specifically hybridizes to [SEQ ID NO:183, SEQ ID NO:184, SEQ ID NO:194, SEQ ID NO:195,] SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, or SEQ ID NO:202.

REMARKS

In response to the Office Action dated August 12, 2002 Applicant hereby elects Group IC, drawn to polynucleotides encoding human persephin polypeptides, vectors, and associated host cells. The claims have been amended to remove references to non-human sequences, as suggested by the Examiner. Applicant reserves the right to prosecute the claims of the non-elected groups in another application.

At part 4, the Examiner suggests that SEQ ID Nos 203 and 205, 204 and 206, 213 and 215, 214 and 216, 207 and 209, 208 and 210, 199 and 201, 200 and 202, respectively are identical. It is suggested that Applicant amend the claims to eliminate